Skip to main content
Home > BioCentury on BioBusiness > Analysts

Chronological Index of : Analyst Picks & Changes

 Current Issue
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 4/29 cls Dynavax Technologies Corp. (NASDAQ:DVAX) RBC Capital Markets Simos Simeonidis Downgrade Sector performer (from outperform) -26…

    Published on 5/2/2016
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 4/22 cls Chiasma Inc. (NASDAQ:CHMA) Cowen Ritu Baral Downgrade Market perform (from outperform) -62% $3.83 William Blair Tim Lugo …

    Published on 4/25/2016
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 4/15 cls Amicus Therapeutics Inc. (NASDAQ:FOLD) Baird Michael Ulz New Neutral -4% $7.75 Ulz initiated coverage with a $9 target. This…

    Published on 4/18/2016
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 4/8 cls Bind Therapeutics Inc. (NASDAQ:BIND) Cowen Eric Schmidt Downgrade Market perform (from outperform) -30% $1.57 JMP Securities…

    Published on 4/11/2016
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 1/1 cls Achaogen Inc. (NASDAQ:AKAO) Cowen Ritu Baral Downgrade Market perform (from outperform) -9% $2.71 Baral downgraded on near-…

    Published on 4/4/2016
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 3/24 cls Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) Goldman Sachs Jami Rubin New Neutral 1% $10.39 Rubin initiated coverage with a $…

    Published on 3/28/2016
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 3/18 cls Epizyme Inc. (NASDAQ:EPZM) H.C. Wainwright Andrew Fein Upgrade Buy (from neutral) 6% $10.96 Fein also raised his target to $…

    Published on 3/21/2016
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 3/11 cls Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Baird Michael Ulz Downgrade Neutral (from outperform) -4% $139.27 Ulz also …

    Published on 3/14/2016
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 3/4 cls Orexigen Therapeutics Inc. (NASDAQ:OREX) RBC Capital Markets Simos Simeonidis Downgrade Sector performer (from outperform) -28%…

    Published on 3/7/2016
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 2/26 cls Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) Baird Brian Skorney Upgrade Outperform (from neutral) 10% $7.35 Skorney …

    Published on 2/29/2016
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 2/19 cls BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stifel, Nicolaus Stephen Willey Upgrade Buy (from hold) 11% $77.70 Willey …

    Published on 2/22/2016
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 2/12 cls BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) Jefferies Brian Abrahams Downgrade Hold (from buy) -72% $1.71 JPMorgan Jessica …

    Published on 2/15/2016
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 2/5 cls Carbylan Therapeutics Inc. (NASDAQ:CBYL) Leerink Partners Jason Gerberry Downgrade Market perform (from outperform) -75% $0.60…

    Published on 2/8/2016
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 1/29 cls Invitae Corp. (NYSE:NVTA) Leerink Partners Dan Leonard Downgrade Market perform (from outperform) -13% $7.00 Leonard also …

    Published on 2/1/2016
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 1/22 cls Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) Piper Jaffray Charles Duncan Upgrade Overweight (from neutral) 3% $24.52 Duncan …

    Published on 1/25/2016
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 1/15 cls Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) Maxim Group Jason McCarthy Upgrade Hold (from sell) -10% $13.00 McCarthy upgraded…

    Published on 1/18/2016
  • Finance

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 1/8 cls Charles River Laboratories International Inc. (NYSE:CRL) Wells Fargo Tim Evans Upgrade Outperform (from market perform) -2% $…

    Published on 1/11/2016
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 12/31 cls ArQule Inc. (NASDAQ:ARQL) RBC Capital Markets Adnan Butt Upgrade Outperform (from sector performer) -3% $2.17 Butt also …

    Published on 1/4/2016
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 12/18 cls Cerus Corp. (NASDAQ:CERS) Wedbush Zarak Khurshid Downgrade Neutral (from outperform) -8% $5.90 Khurshid downgraded, noting …

    Published on 12/21/2015
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 12/11 cls Agios Pharmaceuticals Inc. (NASDAQ:AGIO) Leerink Partners Seamus Fernandez Downgrade Market perform 
(from outperform) -13%…

    Published on 12/14/2015
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 12/4 cls Cepheid Inc. (NASDAQ:CPHD) Wells Fargo Tim Evans Downgrade Market perform (from outperform) -10% $33.43 Evans also lowered …

    Published on 12/7/2015
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 11/20 cls Clovis Oncology Inc. (NASDAQ:CLVS) Mizuho Eric Criscuolo Downgrade Neutral (from buy) -73% $26.41 Criscuolo also lowered …

    Published on 11/23/2015
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 11/13 cls Insmed Inc. (NASDAQ:INSM) UBS Matthew Roden Downgrade Neutral (from buy) -6% $16.05 Roden also lowered his target to $18 …

    Published on 11/16/2015
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 11/6 cls Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) Piper Jaffray Charles Duncan Downgrade Neutral (from overweight) 6% $36.75 Duncan …

    Published on 11/9/2015
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 10/23 cls Biogen Inc. (NASDAQ:BIIB) Baird Brian Skorney Price target Neutral 2% $276.99 H.C. Wainwright Andrew Fein Price target …

    Published on 10/26/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993